CJC-1295 with DAC

CJC-1295 with DAC — Synthetic GHRH Analog

CJC-1295 with DAC is a synthetic 30-amino-acid analog of growth-hormone-releasing factor (GHRH 1-29), modified with four amino-acid substitutions and a Drug Affinity Complex (DAC). The DAC group enables covalent binding to serum albumin, giving the compound a substantially longer plasma half-life than native GHRH — a property that has made it a reference model in research on peptide pharmacokinetics and somatotropic-axis signaling.

What it is studied for

In the published preclinical literature, CJC-1295 with DAC has been investigated in laboratory and in-vitro models for its effects on:

• Growth-hormone & IGF-1 release — sustained stimulation of the somatotropic (GH) axis
• Body composition — models of lean-mass support and fat metabolism
• Recovery & sleep architecture — GH-pulse-related research endpoints
• Extended pharmacokinetics — albumin binding giving a long half-life, used as a reference model

In plain terms: studied for long-acting stimulation of the growth-hormone axis.

Molecular Profile

• Designation: CJC-1295 with DAC (Drug Affinity Complex)
• Structure: Tetra-substituted GHRH(1-29) analog with maleimidopropionyl
• Molecular weight: ~3,647 Da
• Purity: ≥98% (HPLC)
• Format: Sterile lyophilizate in a 10 mg vial

Storage Conditions

• Store at -20 °C, protected from light
• After reconstitution: store at 2–8 °C and use within 28 days

Legal Disclaimer: Reagent intended exclusively for in vitro scientific research by qualified professionals. Not intended for human or veterinary consumption, nor for any therapeutic, diagnostic, or cosmetic purpose. This product is not a medicine, food supplement, or cosmetic. Nexus Peptides accepts no responsibility for any use outside the scope of laboratory research.